Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03718832 · ClinicalTrials.gov registry record · NA

Fresh Food Farmacy: A Randomized Controlled Trial

A NA study of Type 2 Diabetes, sponsored by John B Bulger, DO.

Completed
Registry status
NA
Development phase
500
Enrollment target
2
Study locations

NCT03718832: Completed NA study of Type 2 Diabetes, sponsored by John B Bulger, DO.

NCT03718832 is a NA study of Type 2 Diabetes that has completed, run by John B Bulger, DO. The registered enrollment target is 500 participants, below the 3,922-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03718832, a NA study of Type 2 Diabetes, has completed, sponsored by John B Bulger, DO.

COMPLETED
Registry status
NA
Development phase
500 participants
Enrollment target
2
Study locations

Study Summary

This trial investigates the value created by the highly innovative Fresh Food Farmacy (FFF) program at Geisinger Health. The program provides food-insecure diabetics with healthy food for their entire household: at least two meals per day, five days a week. The program also provides education on how to prepare the food, and education on healthy living including diabetes self management. The research measures the effects of the FFF program on patient health and wellbeing.

Primary Outcome

Glycated hemoglobin (HbA1c) is a measure of the average share of glucose that has been in the bloodstream over the 2-3 months preceding measurement. HbA1c is measured by performing assays on samples of the participants' blood. Units are percentages; for differences between HbA1c values, units are percentage points. An HbA1c value of 6.5% is the lower threshold for type 2 diabetes. HbA1c values are rarely above 15-20%. In the context of this study (patients with type 2 diabetes), higher scores

Conditions Studied

Interventions

  • OTHER Fresh Food Farmacy

Study Locations (2)

Pennsylvania

  • Fresh Food Farmacy - Lewistown
  • Fresh Food Farmacy - Scranton

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2019-04-22
Est. Completion 2023-11-30
Phase NA
John B Bulger, DO

1 total trials

What the finished NCT03718832 record still lists

NCT03718832 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 3,922-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Fresh Food Farmacy is the first listed.

NCT03718832 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03718832 about?

NCT03718832 is a clinical study titled "Fresh Food Farmacy: A Randomized Controlled Trial". This trial investigates the value created by the highly innovative Fresh Food Farmacy (FFF) program at Geisinger Health. The program provides food-insecure diabetics with healthy food for their entire household: at least two meals per day, five days a week. The program also provides education on how...

What is the current status of trial NCT03718832?

This trial is currently completed. It is a NA study. The enrollment target is 500 participants. The study started on 2019-04-22. Estimated completion is 2023-11-30.

What conditions does trial NCT03718832 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT03718832?

The interventions under investigation include: Fresh Food Farmacy (OTHER).

Who is sponsoring clinical trial NCT03718832?

This trial is sponsored by John B Bulger, DO, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03718832 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03718832's enrollment target sits among peer trials

500 44th of 327 higher than 283 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03718832, the US trial registry maintained by the National Library of Medicine. NCT03718832 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.